West Coast, USA-based Forge Therapeutics has inked a deal with Switzerland's Basilea Pharmaceutica to...
San Diego’s Forge Therapeutics has partnered with Basilea Pharmaceutica to develop antibiotics for the Swiss drug company. The deal gives Forge the opportunity [...]
Forge Therapeutics, founded in 2015 with the goal of developing drugs that target metalloenzymes, said Wednesday it had agreed to let Basilea Pharmaceutica [...]
San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea [...]
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. [...]
As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat [...]
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that [...]